Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP

Biogen Inc. BIIB

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$9.9B
▲ 2.2% YoY
$1.3B
▼ 20.8% YoY
$2.1B
▼ 24.7% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA; and QALSODY for the treatment of ALS. It also has collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and with Supernus on the commercialization of ZURZUVAE for the treatment of PPD. The company commercializes a portfolio of biosimilars of advanced biologics, including BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In March 2025 it entered into a lease for approximately 580,000 square feet of office and research and development space at 75 Broadway, Cambridge, Massachusetts, to serve as its new global corporate headquarters integrating its research and development, technical operations, and North American commercial teams.

Written from the business description in BIOGEN INC.'s annual report to the U.S. Securities and Exchange Commission, filed 6 February 2026. Every sentence was checked against that document before publication.

Growth

USD 9.9B
Revenue, FY2025 · full 19-year series below
Revenue $B Net income $B
FY2025 · Revenue 9.9 · Net income 1.3
10B20B
2007201020132016201920222025
Compound annual growth
−0.9%
−6.0%
−0.8%
+5.1%
−24.9%
−20.2%
−9.6%
+1.7%
−25.0%
−18.7%
−5.4%
+5.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −6.0% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

13 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 15.7% · Net 13.1%
20%40%
200720162025
ROE
FY2025 · ROE 7.4%
20%40%
200720162025
Three returns, three denominators.
Return on capital employedNot available: we don't have a clean operating profit figure for this period.

Each USD of equity produced 7 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF 2.1
2.5B5.0B
200720162025
Net buybacks $B Dividends $B
FY2024 · Dividends · · Net buybacks 0.0
2.5B5.0B
2007201020132016201920222024

Total assetsUSD 29.4B
CashUSD 3.0B
Gross debtUSD 6.3B
Net debtUSD 3.3B
Current ratio2.68×

Net debt stands at 18% of equity.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
BIIB, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B9.99.79.810.211.013.414.413.512.311.410.89.76.95.55.04.74.44.13.2
Operating income $B1.61.91.3◌2.84.67.05.95.35.24.94.02.51.91.71.21.31.20.8
EBITDA $B2.32.61.8◌3.35.07.56.56.45.85.54.73.02.22.1◌◌◌◌
Income tax $B0.30.30.10.60.11.01.21.42.51.21.21.00.60.50.40.30.40.40.3
Net income $B1.31.61.23.01.64.05.94.42.53.73.52.91.91.41.21.01.00.80.6
Free cash flow $B2.12.71.31.13.43.86.65.43.74.03.32.72.11.61.51.50.91.30.7
EPS, diluted $8.7911.187.9720.8710.4024.8031.4221.5811.9216.9315.3412.377.815.765.043.943.352.651.99
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————————
ROE %7.410.48.225.114.433.344.634.520.534.435.230.223.920.620.917.316.113.811.5
Shares out B0.150.150.140.140.150.150.170.200.210.220.220.230.240.240.240.240.000.29◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 86 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Two checks were skipped: the balance sheet is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2007

Share this section

Download image